Portfolio Holdings Detail for ISIN IE000T9EOCL3
| Stock Name / Fund | iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc) |
| Issuer | |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | EWSA(USD) Euronext Amsterdam |
Holdings detail for HAE
| Stock Name | Haemonetics Corporation |
| Ticker | HAE(USD) NYSE |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US4050241003 |
| LEI | 549300ZEL6TXZS6F5F95 |
Show aggregate HAE holdings
News associated with HAE
- Haemonetics Corporation (NYSE:HAE) Short Interest Up 41.9% in August
- Haemonetics Corporation (NYSE:HAE – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totaling 4,370,000 shares, a growth of 41.9% from the July 31st total of 3,080,000 shares. Approximately 9.2% of the company’s stock are short sold. Based […] - 2025-09-10 04:58:58
- Haemonetics (NYSE:HAE) Price Target Lowered to $70.00 at Mizuho
- Haemonetics (NYSE:HAE – Free Report) had its target price reduced by Mizuho from $90.00 to $70.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock. A number of other equities analysts also recently commented on the stock. Raymond James Financial reiterated a “strong-buy” rating […] - 2025-08-11 02:56:42
- Brokerages Set Haemonetics Corporation (NYSE:HAE) Target Price at $97.30
- Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation […] - 2025-08-06 02:30:53
- How The Pieces Add Up: SPMD Targets $63
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:27
- Arizona State Retirement System Trims Position in Haemonetics Corporation (NYSE:HAE)
- Arizona State Retirement System cut its holdings in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 3.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 14,407 shares of the medical instruments supplier’s stock after selling 446 shares during the quarter. Arizona State Retirement System’s holdings in Haemonetics were worth $916,000 at […] - 2025-07-21 06:12:11
- Principal Financial Group Inc. Acquires 2,160 Shares of Haemonetics Corporation (NYSE:HAE)
- Principal Financial Group Inc. lifted its stake in Haemonetics Corporation (NYSE:HAE – Free Report) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,894 shares of the medical instruments supplier’s stock after purchasing an additional 2,160 shares during […] - 2025-07-15 05:12:49
- Haemonetics (NYSE:HAE) Raised to Buy at Citigroup
- Haemonetics (NYSE:HAE – Get Free Report) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage presently has a $90.00 target price on the medical instruments supplier’s stock. Citigroup’s target price points to a potential upside of […] - 2025-07-11 02:20:48
- Haemonetics Corporation (NYSE:HAE) Receives Average Rating of “Moderate Buy” from Brokerages
- Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and two […] - 2025-07-09 04:53:34
- KBC Group NV Grows Holdings in Haemonetics Corporation (NYSE:HAE)
- KBC Group NV raised its position in Haemonetics Corporation (NYSE:HAE – Free Report) by 19.9% during the first quarter, Holdings Channel.com reports. The firm owned 2,417 shares of the medical instruments supplier’s stock after buying an additional 401 shares during the period. KBC Group NV’s holdings in Haemonetics were worth $154,000 at the end of […] - 2025-07-07 04:48:46
- Vontobel Holding Ltd. Has $1.01 Million Holdings in Haemonetics Corporation (NYSE:HAE)
- Vontobel Holding Ltd. increased its position in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 21.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,839 shares of the medical instruments supplier’s stock after acquiring an additional 2,828 shares during the period. Vontobel […] - 2025-07-06 06:01:06
- Analysts Predict 15% Gains Ahead For IJJ
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-26 12:59:11
- Haemonetics Co. (NYSE:HAE) Shares Bought by Rhumbline Advisers
- Rhumbline Advisers increased its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 1.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 161,123 shares of the medical instruments supplier’s stock after acquiring an additional 1,861 shares during […] - 2025-06-10 04:54:58
- Two Sigma Investments LP Decreases Holdings in Haemonetics Co. (NYSE:HAE)
- Two Sigma Investments LP trimmed its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 24.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 58,799 shares of the medical instruments supplier’s stock after selling 18,675 shares during the quarter. Two Sigma Investments LP’s holdings in Haemonetics were worth $4,591,000 at the end […] - 2025-05-28 05:52:51
- Nuveen Asset Management LLC Lowers Stock Holdings in Haemonetics Co. (NYSE:HAE)
- Nuveen Asset Management LLC lowered its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 161,452 shares of the medical instruments supplier’s stock after selling 19,887 shares during the quarter. […] - 2025-05-27 04:44:56
- Analysts Set Haemonetics Co. (NYSE:HAE) PT at $97.89
- Shares of Haemonetics Co. (NYSE:HAE – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and […] - 2025-05-23 03:14:52
- Nomura Holdings Inc. Invests $519,000 in Haemonetics Co. (NYSE:HAE)
- Nomura Holdings Inc. purchased a new position in Haemonetics Co. (NYSE:HAE – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,652 shares of the medical instruments supplier’s stock, valued at approximately $519,000. A number of other hedge funds have also recently made changes […] - 2025-05-22 06:48:56
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,084 Shares of Haemonetics Co. (NYSE:HAE)
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,570 shares of the medical instruments supplier’s stock after purchasing an additional 1,084 shares during the […] - 2025-05-22 05:50:49
- Captrust Financial Advisors Grows Position in Haemonetics Co. (NYSE:HAE)
- Captrust Financial Advisors raised its position in Haemonetics Co. (NYSE:HAE – Free Report) by 14.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,872 shares of the medical instruments supplier’s stock after purchasing an additional 624 shares during the […] - 2025-05-20 04:50:49
- Haemonetics (NYSE:HAE) Lowered to “Hold” Rating by StockNews.com
- Haemonetics (NYSE:HAE – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday. HAE has been the topic of several other reports. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price […] - 2025-05-15 02:56:49
- Schonfeld Strategic Advisors LLC Reduces Position in Haemonetics Co. (NYSE:HAE)
- Schonfeld Strategic Advisors LLC lessened its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 13.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,266 shares of the medical instruments supplier’s stock after selling 672 shares during the period. […] - 2025-05-13 05:38:48
- Stifel Financial Corp Grows Position in Haemonetics Co. (NYSE:HAE)
- Stifel Financial Corp lifted its position in Haemonetics Co. (NYSE:HAE – Free Report) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,776 shares of the medical instruments supplier’s stock after purchasing an additional 1,006 shares during the quarter. Stifel […] - 2025-05-09 05:26:56
- Analysts Set Haemonetics Co. (NYSE:HAE) Price Target at $101.22
- Haemonetics Co. (NYSE:HAE – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has issued […] - 2025-04-28 02:39:01
- Envestnet Asset Management Inc. Buys 4,217 Shares of Haemonetics Co. (NYSE:HAE)
- Envestnet Asset Management Inc. boosted its stake in Haemonetics Co. (NYSE:HAE – Free Report) by 9.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,068 shares of the medical instruments supplier’s stock after purchasing an additional 4,217 shares during the […] - 2025-04-25 04:40:56
- Bank of Montreal Can Sells 12,518,398 Shares of Haemonetics Co. (NYSE:HAE)
- Bank of Montreal Can decreased its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 99.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,933 shares of the medical instruments supplier’s stock after selling 12,518,398 shares during the quarter. Bank of Montreal Can’s holdings in Haemonetics were worth $619,000 as of […] - 2025-04-21 05:18:52
- Federated Hermes Inc. Trims Holdings in Haemonetics Co. (NYSE:HAE)
- Federated Hermes Inc. reduced its holdings in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 10.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,554 shares of the medical instruments supplier’s stock after selling 436 shares during the period. Federated Hermes Inc.’s holdings in Haemonetics […] - 2025-04-18 04:59:07
- Haemonetics Co. (NYSE:HAE) Holdings Raised by Pictet Asset Management Holding SA
- Pictet Asset Management Holding SA lifted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 16.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,963 shares of the medical instruments supplier’s stock after acquiring an additional 979 […] - 2025-04-09 05:42:56
- KLP Kapitalforvaltning AS Makes New Investment in Haemonetics Co. (NYSE:HAE)
- KLP Kapitalforvaltning AS acquired a new stake in Haemonetics Co. (NYSE:HAE – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund acquired 10,100 shares of the medical instruments supplier’s stock, valued at approximately $789,000. A number of other hedge funds also recently modified their holdings of HAE. Wellington Management Group LLP raised its […] - 2025-04-01 05:14:58
- 15,294 Shares in Haemonetics Co. (NYSE:HAE) Bought by Natixis Advisors LLC
- Natixis Advisors LLC acquired a new stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund acquired 15,294 shares of the medical instruments supplier’s stock, valued at approximately $1,194,000. A number of other hedge funds have also recently modified their holdings of HAE. Parkside Financial Bank […] - 2025-03-26 05:54:45
- Zurcher Kantonalbank Zurich Cantonalbank Acquires 1,202 Shares of Haemonetics Co. (NYSE:HAE)
- Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Haemonetics Co. (NYSE:HAE – Free Report) by 10.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,460 shares of the medical instruments supplier’s stock after acquiring an additional 1,202 shares during the period. Zurcher […] - 2025-03-21 06:08:54
- Needham & Company LLC Has Lowered Expectations for Haemonetics (NYSE:HAE) Stock Price
- Haemonetics (NYSE:HAE – Get Free Report) had its target price cut by stock analysts at Needham & Company LLC from $108.00 to $104.00 in a report issued on Tuesday, Marketbeat reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s target price indicates a potential upside of […] - 2025-03-20 04:28:54
iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc) HAE holdings
| Date | Number of HAE Shares Held | Base Market Value of HAE Shares | Local Market Value of HAE Shares | Change in HAE Shares Held | Change in HAE Base Value | Current Price per HAE Share Held | Previous Price per HAE Share Held |
|---|
| 2025-11-27 (Thursday) | 969 | USD 78,247 | USD 78,247 | 0 | USD 0 | USD 80.7503 | USD 80.7503 |
| 2025-11-26 (Wednesday) | 969 | USD 78,247 | USD 78,247 | 0 | USD 117 | USD 80.7503 | USD 80.6295 |
| 2025-11-25 (Tuesday) | 969 | USD 78,130 | USD 78,130 | 0 | USD 959 | USD 80.6295 | USD 79.6398 |
| 2025-11-24 (Monday) | 969 | USD 77,171 | USD 77,171 | 0 | USD 823 | USD 79.6398 | USD 78.7905 |
| 2025-11-21 (Friday) | 969 | USD 76,348 | USD 76,348 | 0 | USD 3,557 | USD 78.7905 | USD 75.1197 |
| 2025-11-20 (Thursday) | 969 | USD 72,791 | USD 72,791 | 0 | USD -68 | USD 75.1197 | USD 75.1899 |
| 2025-11-19 (Wednesday) | 969 | USD 72,859 | USD 72,859 | 0 | USD 765 | USD 75.1899 | USD 74.4004 |
| 2025-11-18 (Tuesday) | 969 | USD 72,094 | USD 72,094 | 0 | USD 78 | USD 74.4004 | USD 74.3199 |
| 2025-11-17 (Monday) | 969 | USD 72,016 | USD 72,016 | 0 | USD 804 | USD 74.3199 | USD 73.4902 |
| 2025-11-14 (Friday) | 969 | USD 71,212 | USD 71,212 | 0 | USD -407 | USD 73.4902 | USD 73.9102 |
| 2025-11-13 (Thursday) | 969 | USD 71,619 | USD 71,619 | 0 | USD 766 | USD 73.9102 | USD 73.1197 |
| 2025-11-12 (Wednesday) | 969 | USD 70,853 | USD 70,853 | 0 | USD 1,347 | USD 73.1197 | USD 71.7296 |
| 2025-11-11 (Tuesday) | 969 | USD 69,506 | USD 69,506 | 62 | USD 5,581 | USD 71.7296 | USD 70.4796 |
| 2025-11-10 (Monday) | 907 | USD 63,925 | USD 63,925 | 0 | USD 1,922 | USD 70.4796 | USD 68.3605 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of HAE by for IE000T9EOCL3
Show aggregate share trades of HAE| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-11 | BUY | 62 | 72.720 | 70.520 | 70.740 | USD 4,386 | 64.85 |
| 2025-09-25 | SELL | -1,103 | 47.670 | 50.650 | 50.352 | USD -55,538 | 67.79 Profit of 19,236 on sale |
| 2025-07-31 | BUY | 156 | 74.040 | 75.650 | 75.489 | USD 11,776 | 67.97 |
| 2025-06-17 | BUY | 156 | 69.010 | 70.100 | 69.991 | USD 10,919 | 65.12 |
| 2025-05-14 | BUY | 624 | 68.650 | 69.190 | 69.136 | USD 43,141 | 63.13 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of HAE
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 354,119 | 0 | 830,764 | 42.6% |
| 2025-09-18 | 165,129 | 0 | 510,268 | 32.4% |
| 2025-09-17 | 210,113 | 2,950 | 595,726 | 35.3% |
| 2025-09-16 | 228,007 | 0 | 504,665 | 45.2% |
| 2025-09-15 | 191,132 | 169 | 535,242 | 35.7% |
| 2025-09-12 | 296,048 | 0 | 699,589 | 42.3% |
| 2025-09-11 | 137,190 | 7,500 | 413,250 | 33.2% |
| 2025-09-10 | 160,619 | 0 | 261,604 | 61.4% |
| 2025-09-09 | 124,201 | 0 | 216,081 | 57.5% |
| 2025-09-08 | 140,351 | 31 | 261,726 | 53.6% |
| 2025-09-05 | 104,148 | 35 | 220,003 | 47.3% |
| 2025-09-04 | 170,747 | 3 | 336,871 | 50.7% |
| 2025-09-03 | 134,733 | 6,400 | 316,354 | 42.6% |
| 2025-09-02 | 126,543 | 0 | 268,594 | 47.1% |
| 2025-08-29 | 110,285 | 12,230 | 336,546 | 32.8% |
| 2025-08-28 | 119,351 | 0 | 251,761 | 47.4% |
| 2025-08-27 | 82,519 | 0 | 166,918 | 49.4% |
| 2025-08-26 | 149,380 | 0 | 247,210 | 60.4% |
| 2025-08-25 | 162,477 | 0 | 272,536 | 59.6% |
| 2025-08-22 | 195,123 | 104 | 363,805 | 53.6% |
| 2025-08-21 | 148,906 | 3,100 | 285,788 | 52.1% |
| 2025-08-20 | 202,369 | 0 | 435,126 | 46.5% |
| 2025-08-19 | 160,660 | 2,200 | 437,044 | 36.8% |
| 2025-08-18 | 132,761 | 13 | 270,688 | 49.0% |
| 2025-08-15 | 219,104 | 0 | 386,110 | 56.7% |
| 2025-08-14 | 225,751 | 0 | 587,561 | 38.4% |
| 2025-08-13 | 206,586 | 2,145 | 441,053 | 46.8% |
| 2025-08-12 | 227,869 | 350 | 547,613 | 41.6% |
| 2025-08-11 | 232,180 | 1,249 | 509,661 | 45.6% |
| 2025-08-08 | 285,334 | 5,219 | 793,667 | 36.0% |
| 2025-08-07 | 774,840 | 21,964 | 2,347,232 | 33.0% |
| 2025-08-06 | 225,599 | 0 | 338,293 | 66.7% |
| 2025-08-05 | 149,306 | 0 | 376,326 | 39.7% |
| 2025-08-04 | 81,220 | 0 | 148,176 | 54.8% |
| 2025-08-01 | 111,126 | 0 | 180,253 | 61.7% |
| 2025-07-31 | 133,748 | 0 | 236,451 | 56.6% |
| 2025-07-30 | 121,016 | 0 | 160,320 | 75.5% |
| 2025-07-29 | 87,841 | 10 | 145,552 | 60.4% |
| 2025-07-28 | 68,988 | 0 | 101,947 | 67.7% |
| 2025-07-25 | 67,269 | 0 | 108,369 | 62.1% |
| 2025-07-24 | 120,933 | 0 | 199,018 | 60.8% |
| 2025-07-23 | 70,581 | 0 | 139,281 | 50.7% |
| 2025-07-22 | 99,302 | 0 | 181,521 | 54.7% |
| 2025-07-21 | 122,507 | 0 | 250,689 | 48.9% |
| 2025-07-18 | 96,877 | 0 | 360,834 | 26.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.